Christopher J. Kirk

Christopher J. Kirk

Auto-generated profile, based on publicly available information

Christopher J. Kirk

Onyx Pharmaceuticals, South San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2014 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
Michael BaslerMichael Basler
Michael Basler
SMSarah Mundt
Sarah Mundt
TMTony Muchamuel
Tony Muchamuel
CMCarlo Moll
Carlo Moll
JJJing Jiang
Jing Jiang
CKChristopher J. Kirk
Christopher J. Kirk
Multiple sclerosis (MS) is a chronic demyelinating immune mediated disease of the central nervous system. The immunoproteasome is a distinct class of proteasomes found predominantly in monocytes and lymphocytes. Recently, we demonstrated a novel function of immunoproteasomes in cytokine production and T cell differentiation. In this study, we investigated the therapeutic efficacy of an inhibitor of the immunoproteasome (ONX 0914) in two different mouse models of MS. ONX 0914 attenuated disease progression after active and passive induction of experimental autoimmune encephalomyelitis (EAE), both in MOG 35–55 and PLP 139–151 ‐induced EAE. Isolation of lymphocytes from the brain or spinal cord revealed a strong reduction of cytokine‐producing CD4 + cells in ONX 0914 treated mice. Additionally, ONX 0914 treatment prevented disease exacerbation in a relapsing‐remitting model. An analysis of draining lymph nodes after induction of EAE revealed that the differentiation to Th17 or Th1 cells was strongly impaired in ONX 0914 treated mice. These results implicate the immunoproteasome in the development of EAE and suggest that immunoproteasome inhibitors are promising drugs for the treatment of MS.

13 January 2014 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
DNDenise Niewerth
Denise Niewerth
Gertjan KaspersGertjan Kaspers
Gertjan Kaspers
Yehuda G. AssarafYehuda G. Assaraf
Yehuda G. Assaraf
JMJohan van Meerloo
Johan van Meerloo
CKChristopher J Kirk
Christopher J Kirk
JCJacqueline Cloos
Jacqueline Cloos
Despite encouraging results with the proteasome inhibitor bortezomib in the treatment of hematologic malignancies, emergence of resistance can limit its efficacy, hence calling for novel strategies to overcome bortezomib-resistance. We previously showed that bortezomib-resistant human leukemia cell lines expressed significantly lower levels of immunoproteasome at the expense of constitutive proteasomes, which harbored point mutations in exon 2 of the PSMB5 gene encoding the β5 subunit. Here we investigated whether up-regulation of immunoproteasomes by exposure to interferon-γ restores sensitivity to bortezomib in myeloma and leukemia cell lines with acquired resistance to bortezomib.

1 May 2014 in Biochemical Pharmacology
Verified
Journal Article
Closed access
DNDenise Niewerth
Denise Niewerth
JMJohan van Meerloo
Johan van Meerloo
GJGerrit Jansen
Gerrit Jansen
Yehuda G. AssarafYehuda G. Assaraf
Yehuda G. Assaraf
THTessa C. Hendrickx
Tessa C. Hendrickx
JCJacqueline Cloos
Jacqueline Cloos

10 January 2013 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
SVSue Ellen Verbrugge
Sue Ellen Verbrugge
MAMarjon Al
Marjon Al
YAYehuda G Assaraf
Yehuda G Assaraf
DNDenise Niewerth
Denise Niewerth
JMJohan van Meerloo
Johan van Meerloo
GJGerrit Jansen
Gerrit Jansen
Background: In clinical and experimental settings, antibody-based anti-CD20/rituximab and small molecule proteasome inhibitor (PI) bortezomib (BTZ) treatment proved effective modalities for B cell depletion in lymphoproliferative disorders as well as autoimmune diseases. However, the chronic nature of these diseases requires either prolonged or re-treatment, often with acquired resistance as a consequence. Methods: Here we studied the molecular basis of acquired resistance to BTZ in JY human B lymphoblastic cells following prolonged exposure to this drug and examined possibilities to overcome resistance by next generation PIs and anti-CD20/rituximab-mediated complement-dependent cytotoxicity (CDC). Results: Characterization of BTZ-resistant JY/BTZ cells compared to parental JY/WT cells revealed the following features: (a) 10–12 fold resistance to BTZ associated with the acquisition of a mutation in the PSMB5 gene (encoding the constitutive β5 proteasome subunit) introducing an amino acid substitution (Met45Ile) in the BTZ-binding pocket, (b) a significant 2–4 fold increase in the mRNA and protein levels of the constitutive β5 proteasome subunit along with unaltered immunoproteasome expression, (c) full sensitivity to the irreversible epoxyketone-based PIs carfilzomib and (to a lesser extent) the immunoproteasome inhibitor ONX 0914. Finally, in association with impaired ubiquitination and attenuated breakdown of CD20, JY/BTZ cells harbored a net 3-fold increase in CD20 cell surface expression, which was functionally implicated in conferring a significantly increased anti-CD20/rituximab-mediated CDC. Conclusions: These results demonstrate that acquired resistance to BTZ in B cells can be overcome by next generation PIs and by anti-CD20/rituximab-induced CDC, thereby paving the way for salvage therapy in BTZ-resistant disease.

1 July 2012 in Seminars in Hematology
Verified
Journal Article
Closed access
CKChristopher J. Kirk
Christopher J. Kirk